Skip to main content
Defiance International

Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.

Study record. Trials, 2023. No summary is published for it.

  • 2023

Authorship

No summary is published for this record. No date is promised for one.

Verification: PMID confirmed at PubMed

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

PMID confirmed at PubMed

Open declared source

Key facts

Design
Design subtype not established
System
Not reported
Scale
Not reported
Comparator
None reported
Journal
Trials
Year
2023
PMID
38082326
Verification
PMID confirmed at PubMed The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Bibliographic details only

Technical summary

No technical summary is published for this record.

Limitations and uncertainty

Not reported in the declared source.

Cite

Cite the study

Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
Snyder EL, Sekela ME, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, Beaver TM, Pelletier JPR, Gorham JD, McNeil JS, Sniecinski RM, Pearl RG, Nuttall GA, Sarode R, Reece TB, Kaplan A, Davenport RD, Ipe TS, Benharash P, Lopez-Plaza I, Gammon RR, Sadler P, Pitman JP, Liu K, Bentow S, Corash L, Mufti N, Varrone J, Benjamin RJ, for the ReCePI study group. Trials. 2023. PMID 38082326. DOI 10.1186/s13063-023-07831-x

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.